Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIAsk in your own words. Each question is answered independently.
Select a question to fill the editor, then ask it or make it your own.
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| mouse origin | 5314 | 1020748-57-5 |
| Molecule | Description |
|---|---|
|
Synonyms:
|
Moxetumomab pasudotox-tdfk is a CD22-directed cytotoxin. Moxetumomab pasudotox-tdfk binds CD22 on the cell surface of B-cells and is internalized. Moxetumomab pasudotox -tdfk internalization results in ADP-ribosylation of elongation factor 2, inhibition of protein synthesis, and apoptotic cell death.
|
None
None
None
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Feb. 8, 2021 | EMA | ASTRAZENECA AB | |
| Sept. 13, 2018 | FDA | ASTRAZENECA AB |
None
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Haemolytic uraemic syndrome | 59.74 | 59.30 | 8 | 25 | 2471 | 42618831 |
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Haemolytic uraemic syndrome | 69.54 | 61.85 | 9 | 28 | 4976 | 110584286 |
None
| Source | Code | Description |
|---|---|---|
| ATC | L01FB02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES CD22 (Clusters of Differentiation 22) inhibitors |
| MeSH PA | D000922 | Immunotoxins |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D007155 | Immunologic Factors |
| MeSH PA | D009676 | Noxae |
| MeSH PA | D018796 | Immunoconjugates |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Hairy cell leukemia | indication | 118613001 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| B-cell receptor CD22 | Membrane receptor | BINDING AGENT | Kd | 8.20 | IUPHAR | DRUG LABEL |
| ID | Source |
|---|---|
| 2NDX4B6N8F | UNII |
| 4037930 | VANDF |
| 4037931 | VANDF |
| C2717021 | UMLSCUI |
| CHEBI:750121 | CHEBI |
| CHEMBL1743043 | ChEMBL_ID |
| DB12688 | DRUGBANK_ID |
| D09932 | KEGG_DRUG |
| 9236 | INN_ID |
| 7675 | IUPHAR_LIGAND_ID |
| C541974 | MESH_SUPPLEMENTAL_RECORD_UI |
| C077810 | MESH_SUPPLEMENTAL_RECORD_UI |
| 781124007 | SNOMEDCT_US |
| 781155001 | SNOMEDCT_US |
| 289722 | MMSL |
| 34970 | MMSL |
| 34996 | MMSL |
| d08898 | MMSL |
| 3035755 | PUBCHEM_CID |
| 017804 | NDDF |
| 2099295 | RXNORM |
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| LUMOXITI | HUMAN PRESCRIPTION DRUG LABEL | 1 | 73380-4700 | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | 1 mg | INTRAVENOUS | BLA | 31 sections |